COMP <GO>
UTHR vs MRK // 10Y YIELD & FRED MACRO BETA
United Therapeutics Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: UTHR 11
— MRK 4
▲ 10Y YIELD & FRED MACRO BETA LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
macro-sensitivity
0.95
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 74.80% | +13.10 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 20.70% | -0.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 15.3x | -2.80 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 3.42% | +0.67 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | 34.30% | +12.60 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 28.10% | +13.80 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 1.30% | +9.30 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 5.19 | +17.33 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.1 | 56.9 | +13.26 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.92 | +0.03 | UTHR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 18.4x | -0.60 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $361.02B | -$335.56B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | MRK REV | UTHR GROSS % | MRK GROSS % | UTHR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $65.01B | 87.9% | 74.8% | $1.04B | $12.36B |
| FY 2024 | $2.88B | $64.17B | 89.2% | 76.3% | $1.08B | $18.10B |
| FY 2023 | $2.33B | $60.12B | 44.0% | 44.0% | $873.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
MRK // BETA 0.92